Related references
Note: Only part of the references are listed.Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Hagop M. Kantarjian et al.
LEUKEMIA (2021)
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
Tim H. Bruemmendorf et al.
ANNALS OF HEMATOLOGY (2020)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Andreas Hochhaus et al.
LEUKEMIA (2020)
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
Susan Branford
HAEMATOLOGICA (2020)
Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Ruth Stuckey et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2020)
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Jorge E. Cortes et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
H. J. Khoury et al.
ANNALS OF ONCOLOGY (2018)
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros et al.
BLOOD REVIEWS (2018)
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
Carlo Gambacorti-Passerini et al.
HAEMATOLOGICA (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
Carlo Gambacorti-Passerini et al.
HAEMATOLOGICA (2018)
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Jorge E. Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
Susanne Isfort et al.
JOURNAL OF BLOOD MEDICINE (2018)
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki et al.
CANCER (2018)
Long-Term Patient-Reported Outcomes From an Open-Label Safety and Efficacy Study of Bosutinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients Resistant or Intolerant to Prior Therapy
Hagop M. Kantarjian et al.
CANCER (2018)
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Tim H. Bruemmendorf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Musa Yilmaz et al.
CANCER (2015)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
Tim H. Bruemmendorf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
